预约演示
更新于：2025-07-24
Brimonidine Tartrate/Timolol Maleate
溴莫尼定噻吗洛尔
更新于：2025-07-24
概要
基本信息
药物类型 小分子化药 |
别名 AIBETA COMBINATION OPHTHALMIC SOLUTION、Brimonidine Tartrate and Timolol Maleate、Brimonidine/timolol + [7] |
作用方式 激动剂、拮抗剂 |
作用机制 ADRA2激动剂(肾上腺素能受体α-2家族激动剂)、β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
治疗领域 |
非在研适应症- |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H16BrN5O6 |
InChIKeyQZHBYNSSDLTCRG-LREBCSMRSA-N |
CAS号70359-46-5 |
查看全部结构式(2)
关联
30
项与 溴莫尼定噻吗洛尔 相关的临床试验CTIS2023-507285-24-00
Non-inferiority Clinical Trial for Comparing the Efficacy and Tolerability of a new fixed-Combination Generic Formulation of Brimonidine 0.2%/Timolol 0.5% eye drops, solution in single-dose containers vs Combigan® eye drops, solution in Patients with Open Angle Glaucoma or Ocular Hypertension - BECRO/PS/ETHRA
CTRI/2021/12/038477
A multicentre, randomized, assessor-blinded, active controlled, parallel group, two arm, bioequivalence study with clinical endpoint to assess non-inferiority of Brimonidine tartrate 2 mg/ml & Timolol 5 mg/ml preservative-free eye drops solution (Pharmathen S.A, Greece) to Combigan (Brimonidine tartrate 2 mg/ml & Timolol 5 mg/ml) eye drops solution (Allergan Pharmaceuticals Ireland, Ireland) in the treatment of elevated intraocular pressure in adult patients with chronic open-angle glaucoma or ocular hypertension.
NCT06078592
Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN- PLUS® Eye Drops and COMBIGAN® Eye Drops in Glaucoma or Ocular Hypertensive Patients
100 项与 溴莫尼定噻吗洛尔 相关的临床结果
登录后查看更多信息
100 项与 溴莫尼定噻吗洛尔 相关的转化医学
登录后查看更多信息
100 项与 溴莫尼定噻吗洛尔 相关的专利（医药）
登录后查看更多信息
14
项与 溴莫尼定噻吗洛尔 相关的文献（医药）2023-09-01Advances in therapy
Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study.
Article
作者: Ozaki, Mineo ; Ishiyama, Sosuke ; Kuwamura, Rika ; Sunagawa, Hiromi ; Otani, Shinichiro ; Nakamura, Makoto ; Nakakura, Shunsuke ; Watanabe-Kitamura, Fumika ; Mori, Sotaro ; Inoue, Toshihiro ; Lee, Jinhee ; Tsutsui, Aika ; Kanamori, Akiyasu ; Ishida, Akiko ; Yamashita, Takehiro ; Tanito, Masaki ; Shiokawa, Minako ; Oi, Junko ; Yoshida, Akiko ; Murai, Yusuke ; Kido, Noriaki ; Sagara, Takeshi ; Abe, Hideki ; Suzuki, Katsuyoshi ; Tanabe, Hirotaka ; Aoki, Ryota ; Kurimoto, Takuji ; Matsuyama, Akiko ; Kuwayama, Yasuaki ; Sakono, Takato ; Saito, Yoshiaki ; Inoue, Kenji ; Sameshima, Motoyasu ; Inatani, Masaru ; Orii, Yusuke ; Ueda, Kaori ; Musashi, Kunihiro ; Hayashi, Ken ; Kagaya, Fumie ; Manabe, Shinichi ; Kano, Kiyoshi ; Sakono, Takuto ; Arimura, Shogo ; Nakagawa, Satoko ; Inoue, Chizuru ; Yamada-Nakanishi, Yuko ; Urahashi, Mai ; Manabe, Kaoru ; Iwasaki, Kentaro ; Takaki, Keiko
INTRODUCTION:
This multicenter, randomized, comparative, and investigator-masked crossover clinical trial sought to compare the efficacy and tolerability of fixed combinations of 0.1% brimonidine/0.5% timolol (BTFC) versus 1% dorzolamide/0.5% timolol (DTFC) as adjunctive therapies to prostaglandin analogues.
METHODS:
A total of 110 patients with open-angle glaucoma or ocular hypertension previously treated with prostaglandin analogue monotherapy were randomized to receive either BTFC or DTFC as adjunctive therapy for 8 weeks. These patients were then crossed over to the alternative treatment arm for another 8 weeks. The reduction in intraocular pressure (IOP) (primary outcome), occurrence of adverse events, ocular discomfort after instillation, and patient preference (secondary outcomes) were recorded through patient interviews.
RESULTS:
BTFC instillation for 8 weeks reduced IOP by 3.55 mmHg, demonstrating non-inferiority to DTFC instillation (3.60 mmHg; P < 0.0001, mixed-effects model). Although adverse events were rare with both combinations, patients reported greater discomfort with DTFC than with BTFC (P < 0.0001). More patients preferred BTFC (P < 0.0001) over DTFC, as BTFC caused minimal or no eye irritation.
CONCLUSION:
As BTFC offered better tolerability than DTFC with comparable reduction in IOP, we recommend it as an alternative for patients who experience ocular discomfort with DTFC-prostaglandin analogue combination therapy.
TRIAL REGISTRATION NUMBER:
jRCTs051190125.
2020-09-01American journal of ophthalmology case reports
A case of the blues: Inadvertent ocular injury from accidental instillation of blue ink
作者: Port, Alexander D ; Sippel, Kimberly C ; Brissette, Ashley R
PURPOSE:
Many consumer products and non-ophthalmic medications are packaged in plastic "eye dropper" bottles, posing a risk of accidental ocular chemical injury when these substances are mistaken for eye drops.
OBSERVATIONS:
We present the case of an elderly glaucoma patient who mistook blue stamper ink for the glaucoma medication Combigan®, and suffered ocular injury as a result.
CONCLUSIONS AND IMPORTANCE:
The packaging of non-ophthalmic products in plastic "eye dropper" bottles poses a significant risk of accidental ocular chemical injury. Elderly individuals with low vision and/or cognitive deficits may be at particular risk of accidental injury. Ophthalmologists have been calling for a greater distinction between the packaging of ophthalmic and non-ophthalmic products for over 35 years, but to date little progress has been made in this regard.
2016-07-01Pediatric dermatology
Brimonidine Toxicity Secondary to Topical Use for an Ulcerated Hemangioma
作者: Gill, Kamalvir ; Golden, Alex ; Desai, Ritu ; Tamburro, Joan ; Raimer, Patricia ; Bayart, Cheryl
Abstract:
Combigan (Allergan, Irvine, CA) is an ophthalmic solution that combines 0.2% brimonidine, a selective α‐2 adrenergic agonist, with 0.5% timolol, a nonselective β‐adrenergic antagonist. It is approved for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. There have been recent reports of successful treatment of superficial infantile hemangiomas (IHs) using Combigan topically. We report the case of a 2‐month‐old girl who developed life‐threatening brimonidine toxicity requiring intubation and mechanical ventilation secondary to central nervous system depression and apnea after topical application to an ulcerated IH.
100 项与 溴莫尼定噻吗洛尔 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 日本 | 2019-09-20 | |
| 开角型青光眼 | 澳大利亚 | 2005-01-07 | |
| 高眼压症 | 澳大利亚 | 2005-01-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 110 | 獵簾鹽積獵鏇窪淵窪醖(網築簾淵齋願積壓膚夢) = 觸鹽鹹壓夢餘鬱襯築積 製觸選選廠構鑰鏇築鏇 (願衊繭齋選鏇齋衊衊艱 ) | 积极 | 2023-04-23 | ||
獵簾鹽積獵鏇窪淵窪醖(網築簾淵齋願積壓膚夢) = 製製製鹹獵獵鹹積醖醖 製觸選選廠構鑰鏇築鏇 (願衊繭齋選鏇齋衊衊艱 ) | |||||||
N/A | - | - | 鹹鏇積範願範齋網獵淵(網齋選鹹糧襯廠襯壓憲) = CNS and respiratory depression were observed in the 3 neonates within 2 hours of administration of brimonidine tartrate 0.2% â timolol maleate 0.5% eye drops 艱壓觸醖夢糧窪獵齋壓 (範醖構餘窪築鹽衊願壓 ) 更多 | - | 2019-03-06 | ||
N/A | - | 266 | Fixed combination therapy of brimonidine 0.2%-timolol 0.5% | 獵壓製鏇簾積鏇網遞鬱(觸鑰築襯簾憲築廠鹽壓) = Adverse events were more frequent in the FCBT group (65.5%) than the MB group (42.2%) 製願繭襯蓋糧壓鏇鑰糧 (繭鬱鬱膚衊膚鏇築獵積 ) | - | 2015-06-01 | |
临床4期 | 17 | 選選壓壓鹹網蓋醖壓顧(蓋鹽獵積觸夢壓夢範襯) = 齋鬱製鬱夢遞蓋選鑰淵 憲範鏇選窪鹹膚膚鏇艱 (築衊選獵選淵淵齋範壓, 餘構餘積衊繭獵願網齋 ~ 壓觸憲衊簾簾廠範獵構) 更多 | - | 2013-02-06 | |||
临床4期 | 121 | 窪壓範築選顧構鏇鏇鏇(鬱鑰鑰糧艱淵獵壓鬱襯) = 糧窪餘鏇築窪襯願鹹鬱 願壓蓋顧鏇構製觸網網 (築製膚窪願艱範淵構簾, 2.34) 更多 | - | 2012-01-12 | |||
(Lumigan®) | 窪壓範築選顧構鏇鏇鏇(鬱鑰鑰糧艱淵獵壓鬱襯) = 膚襯夢構壓襯蓋醖夢淵 願壓蓋顧鏇構製觸網網 (築製膚窪願艱範淵構簾, 3.42) 更多 | ||||||
临床4期 | 204 | 製網顧築蓋選範獵窪廠(製衊蓋衊築顧艱鹽糧簾) = 廠範醖範選遞獵獵廠築 壓膚齋範築築淵餘襯衊 (構網蓋觸願醖淵艱餘艱, 2.46) 更多 | - | 2011-11-24 | |||
N/A | - | - | 蓋積糧廠夢鏇糧鹽淵積(糧製壓築憲願選窪築願) = 衊鹽淵遞憲艱選範觸鹹 憲齋築顧鬱齋膚積築齋 (蓋窪襯壓鹽繭構衊蓋繭 ) | 积极 | 2011-04-01 | ||
蓋積糧廠夢鏇糧鹽淵積(糧製壓築憲願選窪築願) = 襯願淵鬱網醖築選廠選 憲齋築顧鬱齋膚積築齋 (蓋窪襯壓鹽繭構衊蓋繭 ) | |||||||
N/A | - | Fixed combination of brimonidine/timolol | 襯遞醖蓋鹽鹹壓廠廠鏇(顧蓋窪淵範窪積鏇獵憲) = 鑰簾淵衊鹽繭遞鏇網膚 憲夢餘廠鬱鏇網窪糧壓 (壓廠鏇遞廠獵築糧艱淵 ) | - | 2010-04-01 | ||
2-bottle combination: beta blocker (BB) + brimonidine | 襯遞醖蓋鹽鹹壓廠廠鏇(顧蓋窪淵範窪積鏇獵憲) = 艱網齋獵鏇蓋襯鹹簾衊 憲夢餘廠鬱鏇網窪糧壓 (壓廠鏇遞廠獵築糧艱淵 ) | ||||||
临床3期 | - | Fixed-combination brimonidine-timolol BID | 網醖獵願簾襯廠顧憲餘(鬱糧齋糧廠願範鬱製構) = 鬱觸網顧鑰鹹製鏇壓窪 壓糧選蓋網築積糧齋憲 (醖鏇顧襯鏇選齋膚艱築 ) | - | 2010-04-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用